Angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are frequently used for the treatment for glomerulonephritis and diabetic nephropathy because of their albuminuria-or proteinuria-reducing effects. To many patients who are nonresponsive to monotherapy with these agents, combination therapy appears to be a good treatment option. In the present study, we examined the effects of the addition of an ARB (losartan) followed by titration upon addition and at 3 and 6 months (n =14) and the addition of an ACE-I followed by titration upon addition and at 3 and 6 months (n =20) to the drug regimen treatment protocol in type 2 diabetic patients with nephropathy for whom more than 3-month administration of an ACE-I or the combination of an ACE-I plus a conventional antihypertensive was ineffective to achieve a blood pressure (BP) of 130/80 mmHg and to reduce urinary albumin to <30 mg/day. During the 12-month treatment, addition of losartan or addition of an ACE-I to the treatment protocol reduced systolic blood pressure (SBP) by 10% and 12%, diastolic blood pressure (DBP) by 7% and 4%, and urinary albumin excretion by 38% and 20% of the baseline value, respectively. However, the effects on both BP and urinary albumin were not significantly different between the two therapies. In conclusion, addition of losartan or an ACE-I to an ongoing treatment with an ACE-I, or addition of an ACE-I to ongoing treatment with a conventional antihypertensive were equally effective at reducing the urinary albumin excretion and BP, and 
, Shinya MINATOGUCHI 1) , Hiroshige OHASHI 1) , Ichijiro MURATA 1) , Taro MINAGAWA 1) , Toshio OKUMA 1) , Hitomi YOKOYAMA 1) , Hisato TAKATSU 1) , Tadatake TAKAYA 1) , Toshihiko NAGANO 1) , Yukio OSUMI 1) , Masao KAKAMI 1) , Tatsuo TSUKAMOTO 1) , Tsutomu TANAKA 1) , Kunihiko HIEI 1) , and Hisayoshi FUJIWARA 1) 
Introduction
Diabetic nephropathy affected about 1.5 million people in the year 2002 in Japan. Proteinuria, albuminuria, hypertension and hyperglycemia are strong risk factors for progression of renal dysfunction (1) (2) (3) (4) . Thus, the treatment must be focused on reducing both blood pressure (BP) and proteinuria or albuminuria. Although angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs) are widely used to treat diabetic nephropathy and prevent progressive renal dysfunction by conferring renoprotection and From the 1) Second Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan.
reducing systemic BP (5) (6) (7) (8) , the combination of an ACE-I and an ARB has recently been reported to provide greater renoprotection than monotherapy with either agent alone in patients with IgA nephropathy and type-2 diabetes mellitus (9) (10) (11) . In the present study, we compared the renoprotective effects of adding an ARB (losartan) or adding an ACE-I to the drug regimen treatment protocol in type-2 diabetic patients with nephropathy for whom 3-month treatment with an ACE-I or 3-month treatment with an ACE-I plus a conventional antihypertensive drug was ineffective to reach a BP of 130/85 mmHg and reduce urinary albumin to < 30 mg/day. The relatively low target BP of 130/85 mmHg was assigned because it has been recommended for hypertensive patients who have risk factors for renal disease (12, 13) .
Methods

Study Subjects
In this study, we recruited type-2 diabetic patients aged from 30 to 70 years who had overt nephropathy, albuminuria > 30 mg/day, and BP > 130/80 mmHg even after being treated with an ACE-I or the combination of an ACE-I and conventional 
Study Protocol
We recruited 34 patients who visited Gifu University Hospital from March 2002 to April 2003. Patients for whom an ACE-I or the combination of an ACE-I plus a conventional antihypertensive drug was ineffective in lowering BP to 130/85 mmHg and reducing urinary albumin to < 30 mg/day were allocated into two groups: the losartan add-on group (n= 14) received add-on losartan (25 mg or 50 mg) at month 0, followed by titration every 3 months until their BP fell to less than 130/80 mmHg, and the ACE-I add-on group (n= 20) received add-on ACE-I followed by titration every 3 months until the BP become less than 130/80 mmHg ( Fig. 1 ). Patients took antihypertensive drugs at 7 to 8 AM. We carried out randomization using envelopes. BP was measured using a mercury sphygmomanometer with the subject in a sitting position in the morning (10 or 11 AM) at the clinic, and urinary albumin and Cr excretion were measured and blood tests were given for fasting glucose, HbA1c, uric acid, Cr and blood urea nitrogen (BUN) every 3 months. The study protocol was approved by the ethical committee of the Gifu University School of Medicine. Informed consent was obtained from each patient before the study.
Statistical Analysis
All data obtained are presented as the mean±SD. An unpaired t-test was used to compare the baseline characteristics of mean age, body mass index (BMI), systolic BP (SBP) and DBP, serum Cr, and urinary albumin between the two groups, and Fisher's exact test was used to compare the sex of patients between the two groups. Difference were analyzed in SBP, DBP, urinary albumin and Cr excretion, serum Cr value, fasting blood glucose, HbA1c, serum uric acid, BUN, and serum sodium, potassium and chloride level between two time Urinary Albumin * * * * * points within the group with paired t-test. The difference in parameters of baseline characteristics between the two groups was analyzed with unpaired t-test. p values of less than 0.05 were considered to be statistically significant. All statistical tests were two sided.
Results
As shown in Table 1 , the baseline characteristics of age, BMI, SBP, DBP, serum Cr level, and urinary albumin level were similar between the two groups. However, the proportion of females was higher in the ACE-I add-on group. Table 2 shows the baseline clinical characteristics. There were no significant differences in medical history or baseline treatment between the two groups. Table 3 shows the mean dosage of add-on ACE-I and ARB.
Effect on BP
The time course of changes in BP in response to antihypertensive therapy is shown in Fig. 2 
Effect on Urinary Albumin Excretion
The time course of changes in urinary albumin excretion is shown in Fig. 3 
Effect on the Urinary and Serum Cr Levels and BUN Level
The changes in serum and urinary Cr levels are shown in Fig.  4 . Losartan add-on therapy significantly reduced urinary Cr levels at month 6 (p< 0.05) and month 12 (p< 0.05), but not serum Cr after treatment compared to the baseline values, while ACE-I add-on therapy did not reduce either urinary or serum Cr. Neither therapy had any effect on the BUN levels. 
Effect on the Serum Uric Acid Levels
Losartan add-on therapy but not ACE-I add-on therapy significantly reduced the serum uric acid levels at the month 3, 6, and 12 (all p< 0.05) after the treatment, as shown in Fig. 6 .
Adverse Effects
No serious adverse effects such as an increased serum potassium concentration exceeding 5.5 mEq/L were observed in either group during the study periods.
Discussion
Type 2 diabetic patients with proteinuria and hypertension have a high mortality rate. For these patients, the treatment must be focused on reducing proteinuria as well as lowering BP (14) . Many clinical studies have revealed that both ACEIs and ARBs are effective for conferring renoprotection in patients with type 2 diabetes mellitus (15) (16) (17) (18) (19) by reducing proteinuria and BP. Inhibition of the renin-angiotensin system (RAS) is an important element of the treatment for patients with renal disease and albuminuria. ACE-Is are commonly used for retarding the progression of renal disease by inhibiting the RAS.
However, ACE-Is cannot completely inhibit the RAS, because angiotensin II is produced not only by angiotensin converting enzymes, but also by enzymes such as chymase. Thus, after the long-term use of an ACE-I, the level of circulating angiotensin II returned to the pretreatment level and ACE-I was ineffective. Numerous studies have shown that the combination of an ARB and ACE-I reinforces the blockade of the RAS and reduces urinary protein excretion (for review see Mackinnon et al. (20) ). The synergism of ACE-Is and ARBs was demonstrated in a study using a combination of half doses of each monotherapy in patients with albuminuria (21) . Although in the present study the combination therapy did not have a significant effect on albuminuria, the reduction of albumin excretion with the combination of an ARB and ACE-I tended to be somewhat greater (38%) than that with ACE-I monotherapy (20%) at the 12-month measurement.
In our study, addition of an ARB (losartan) or of an ACE-I for 12 months equally and significantly reduced the mean urinary albumin excretion in patients with diabetic nephropathy for whom the administration of an ACE-I alone or the combination of an ACE-I plus a conventional antihypertensive for more than 3 months was ineffective at reducing the BP to the target of 130/80 mmHg and urinary albumin excretion to < 30 mg/day. There was no difference in the reduction of urinary albumin excretion between the two therapies. There have been many reports on the efficacy of combination therapy with ARBs and ACE-Is, and these studies have clearly shown that the combined therapy produces a more marked reduction in proteinuria as compared to monotherapy with either drug alone in patients with IgA glomerulonephritis (9, 10, 22) , type-2 diabetic nephropathy (23) and type-1 diabetic nephropathy (24) . Add-on therapy of the ARB losartan and add-on therapy of an ACE-I are both effective in reducing the urinary albumin excretion, suggesting that both therapies block the activity of the RAS.
We aimed to lower the BP below 130/80 mmHg with addon therapy, because this goal has been recommended to confer protection against the development of chronic renal disease (25) . Although not all the cases reached the target BP, both losartan add-on therapy and ACE-I add-on therapy reduced the mean SBP and DBP, and these reductions were comparable between the two therapies at 3, 6 and 12 months.
Although both ACE-Is and ARBs are considered safe drugs, hyperkalemia is a known side effect common to both. In the present study, however, no significant change in serum potassium was observed in either treatment group.
In the COOPERATE study (26) , the incidence of hyperkalemia was 7.8% in non-diabetic renal disease patients treated with the combination of losartan 100 mg and trandolapril 3 mg, which was lower than that of trandolapril monotherapy (9.3%). It has been reported that there was no significant change in mean serum potassium level during 4-week dual blockage with the combination of 8 mg of candesartan and 20 mg of both lisinopril/enalapril in patients with (27, 28) . It has also been reported that treatment with the combination of 16 mg of candesartan and 20 mg of lisinopril for 12 months significantly increased the serum concentration of potassium by 0.30 mmol/L in patients with hypertension, microalbuminuria and non-insulin dependent diabetes, but the level was within the normal range and the increase was not considered clinically significant (11) .
Thus, many studies have demonstrated that hyperkalemia is not a significant adverse side effect but must be carefully observed in patients who receive combination therapy with ARBs and ACE-Is. Blood glucose and HbA1c levels were significantly reduced by both the losartan and ACE-I add-on therapies after the 12-month treatment, suggesting that blockade of the RAS may improve glucose metabolism.
The addition of losartan resulted in a significant decrease in serum uric acid levels. The baseline level of uric acid was within the normal range in the study patients.
In conclusion, in patients with type-2 diabetic nephropathy who had been treated with an ACE-I or the combination of an ACE-I plus a conventional hypertensive drug and who had a BP of more than 130/80 mmHg and urinary albumin excretion > 30 mg/day, add-on therapy of either an ARB (losartan) or an ACE-I was equally effective at reducing urinary albumin excretion and treating nephropathy.
